Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Members Call for Tougher Regulations on Drug Rep Activities
November 17, 2017
- Annual Re-Pricing Likely to Start in FY2021 for Scope of Products Defined in 2020
November 17, 2017
- Govt Plans Tiered PMP for Smaller Scope of Products, Post-Z2 Rule for LLPs
November 17, 2017
- MHLW to Launch Study on Leftover Vial Drugs
November 16, 2017
- LDP Study Group on Pharma Policies Submits Resolution to Health Minister
November 16, 2017
- MHLW to Issue Optimal Use Guidelines for Bavencio
November 16, 2017
- Chuikyo OKs Bavencio, Maviret, Ibrance and More for Listing on Nov. 22
November 15, 2017
- Industry Opposes Full Annual Price Revisions at LDP Hearing
November 15, 2017
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- Benralizumab, Olaparib, Keytruda’s Urothelial Carcinoma Use Up for MHLW Panel Review/Report on Nov. 24
November 13, 2017
- Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
- Dispensing of Generics Down Slightly Despite Increase in Generic-Name Prescribing: Chuikyo Survey
November 13, 2017
- Japan, US Agree to Extend Chuikyo’s Industry Hearing Time
November 9, 2017
- 3rd-Party Re-Analysis Now Complete; Chuikyo Discusses Pilot CEA Products Closed Door
November 9, 2017
- Driver Gene-Based Drug Discovery Also Applicable for Early Approval System: MHLW
November 8, 2017
- 3 Japanese Plasma Fraction Product Makers Raise Concerns about Low NHI Prices at MHLW Panel
November 8, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1, Keytruda’s Lymphoma Use and More Clear MHLW Panel
November 7, 2017
- 3 Chuikyo Subcommittees to Hold Close-Door Debate on Pilot CEA Products Nov. 8
November 7, 2017
- LDP Group Starts Discussions on Drug Pricing Reform, Hears Opinions from JPMA Chief
November 6, 2017
- PMDA’s Review Division Remains in the Red, with Loss of 2-2.5 Billion Yen Expected for Full Year
November 6, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…